BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Paul F, Murphy O, Pardo S, Levy M. Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opinion on Investigational Drugs 2018;27:265-71. [DOI: 10.1080/13543784.2018.1443077] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Kuchling J, Paul F. Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Front Neurol 2020;11:450. [PMID: 32625158 DOI: 10.3389/fneur.2020.00450] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
2 Duchow A, Chien C, Paul F, Bellmann-Strobl J. Emerging drugs for the treatment of neuromyelitis optica. Expert Opin Emerg Drugs 2020;25:285-97. [PMID: 32731771 DOI: 10.1080/14728214.2020.1803828] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
3 Asseyer S, Cooper G, Paul F. Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. Front Neurol 2020;11:778. [PMID: 33473247 DOI: 10.3389/fneur.2020.00778] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
4 Gong Y, Zhang YL, Wang Z, Song HH, Liu YC, Lv AW, Tian LL, Zhu WL, Fu Y, Ding XL, Cui LJ, Yan YP. Tanshinone IIA alleviates brain damage in a mouse model of neuromyelitis optica spectrum disorder by inducing neutrophil apoptosis. J Neuroinflammation 2020;17:198. [PMID: 32586353 DOI: 10.1186/s12974-020-01874-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Agasing AM, Wu Q, Khatri B, Borisow N, Ruprecht K, Brandt AU, Gawde S, Kumar G, Quinn JL, Ko RM, Mao-Draayer Y, Lessard CJ, Paul F, Axtell RC. Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica. Nat Commun 2020;11:2856. [PMID: 32503977 DOI: 10.1038/s41467-020-16625-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
6 Berkovich R. Experience of Using Adrenocorticotropic Hormone in the Treatment of Patients With Acute Neuromyelitis Optica Who Failed Systemic Steroids: A Case Series. Clin Neuropharmacol 2020;43:7-14. [PMID: 31876792 DOI: 10.1097/WNF.0000000000000373] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Thoman ME, McKarns SC. Metabolomic Profiling in Neuromyelitis Optica Spectrum Disorder Biomarker Discovery. Metabolites 2020;10:E374. [PMID: 32961928 DOI: 10.3390/metabo10090374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Borisow N, Mori M, Kuwabara S, Scheel M, Paul F. Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. Front Neurol 2018;9:888. [PMID: 30405519 DOI: 10.3389/fneur.2018.00888] [Cited by in Crossref: 105] [Cited by in F6Publishing: 94] [Article Influence: 26.3] [Reference Citation Analysis]
9 Gold SM, Willing A, Leypoldt F, Paul F, Friese MA. Sex differences in autoimmune disorders of the central nervous system. Semin Immunopathol 2019;41:177-88. [PMID: 30361800 DOI: 10.1007/s00281-018-0723-8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 10.5] [Reference Citation Analysis]
10 Xie Q, Sun M, Sun J, Zheng T, Wang M. New progress in the treatment of neuromyelitis optica spectrum disorder with monoclonal antibodies (Review). Exp Ther Med 2021;21:148. [PMID: 33456515 DOI: 10.3892/etm.2020.9579] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Duchow A, Paul F, Bellmann-strobl J. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders. Expert Opinion on Biological Therapy 2020;20:1061-72. [DOI: 10.1080/14712598.2020.1749259] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
12 Lotan I, McGowan R, Levy M. Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy. Curr Neuropharmacol 2021;19:220-32. [PMID: 32348222 DOI: 10.2174/1570159X18666200429010825] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Duan T, Verkman AS. Experimental animal models of aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders: progress and shortcomings. Brain Pathol 2020;30:13-25. [PMID: 31587392 DOI: 10.1111/bpa.12793] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
14 D'Souza M, Papadopoulou A, Levy M, Jacob A, Yeaman MR, Kümpfel T, Marignier R, Paul F, Brandt AU. Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey. Mult Scler Relat Disord 2020;41:102027. [PMID: 32179483 DOI: 10.1016/j.msard.2020.102027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Liu C, Shi M, Zhu M, Chu F, Jin T, Zhu J. Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges. Autoimmun Rev 2021;:102921. [PMID: 34384938 DOI: 10.1016/j.autrev.2021.102921] [Reference Citation Analysis]
16 Ladhani SN, Campbell H, Lucidarme J, Gray S, Parikh S, Willerton L, Clark SA, Lekshmi A, Walker A, Patel S, Bai X, Ramsay M, Borrow R. Invasive meningococcal disease in patients with complement deficiencies: a case series (2008-2017). BMC Infect Dis 2019;19:522. [PMID: 31200658 DOI: 10.1186/s12879-019-4146-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
17 Traub J, Husseini L, Weber MS. B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders. Pharmaceuticals (Basel) 2021;14:37. [PMID: 33419217 DOI: 10.3390/ph14010037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Levy M. Interleukin-6 receptor blockade for the treatment of NMOSD. Lancet Neurol 2020;19:370-1. [PMID: 32333886 DOI: 10.1016/S1474-4422(20)30081-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Cook LJ, Rose JW, Alvey JS, Jolley AM, Kuhn R, Marron B, Pederson M, Enriquez R, Yearley J, McKechnie S, Han MH, Tomczak AJ, Levy M, Mealy MA, Coleman J, Bennett JL, Johnson R, Barnes-Garcia M, Traboulsee AL, Carruthers RL, Lee LE, Schubert JJ, McMullen K, Kister I, Rimler Z, Reid A, Sicotte NL, Planchon SM, Cohen JA, Ivancic D, Sedlak JL, Sand IK, Repovic P, Amezcua L, Pruitt A, Amundson E, Chitnis T, Mullin DS, Klawiter EC, Russo AW, Riley CS, Onomichi KB, Levine L, Nelson KE, Nealon NM, Engel C, Kruse-Hoyer M, Marcille M, Tornes L, Rumpf A, Greer A, Kenneally Behne M, Rodriguez RR, Behne DW, Blackway DW, Coords B, Blaschke TF, Sheard J, Smith TJ, Behne JM, Yeaman MR; Guthy-Jackson Charitable Foundation International Clinical Consortium (GJCF–ICC). Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD. Neurol Neuroimmunol Neuroinflamm 2019;6:e583. [PMID: 31355319 DOI: 10.1212/NXI.0000000000000583] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
20 Chang VTW, Chang HM. Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder. Neuropathol Appl Neurobiol 2020;46:199-218. [PMID: 31353503 DOI: 10.1111/nan.12574] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
21 Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung H, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. The Lancet 2019;394:1352-63. [DOI: 10.1016/s0140-6736(19)31817-3] [Cited by in Crossref: 171] [Cited by in F6Publishing: 88] [Article Influence: 57.0] [Reference Citation Analysis]
22 Zhu W, Zhang Y, Wang Z, Fu Y, Yan Y. Monoclonal Antibody-Based Treatments for Neuromyelitis Optica Spectrum Disorders: From Bench to Bedside. Neurosci Bull 2020;36:1213-24. [PMID: 32533450 DOI: 10.1007/s12264-020-00525-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
23 Schwartz N, Stock AD, Putterman C. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol 2019;15:137-52. [PMID: 30659245 DOI: 10.1038/s41584-018-0156-8] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 36.0] [Reference Citation Analysis]
24 Sharma J, Bhatti MT, Danesh-Meyer HV. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro-ophthalmic review. Clin Exp Ophthalmol 2021;49:186-202. [PMID: 33426799 DOI: 10.1111/ceo.13863] [Reference Citation Analysis]
25 Li W, Liu J, Tan W, Zhou Y. The role and mechanisms of Microglia in Neuromyelitis Optica Spectrum Disorders. Int J Med Sci 2021;18:3059-65. [PMID: 34400876 DOI: 10.7150/ijms.61153] [Reference Citation Analysis]
26 Blackburn KM, Kubiliun M, Harris S, Vernino S. Neurological autoimmune disorders with prominent gastrointestinal manifestations: A review of presentation, evaluation, and treatment. Neurogastroenterology & Motility 2019;31. [DOI: 10.1111/nmo.13611] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Pardo S, Giovannoni G, Hawkes C, Lechner-Scott J, Waubant E, Levy M. Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2019;33:A1-2. [PMID: 31324299 DOI: 10.1016/j.msard.2019.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
28 Mukherjee S, Guha G, Roy M, Ghosh S, Saha SP. A study on patients with neuromyelitis optica spectrum disorder from Eastern India. Neurology, Psychiatry and Brain Research 2020;35:22-8. [DOI: 10.1016/j.npbr.2019.12.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
29 Lana-Peixoto MA, Talim N. Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes. Biomedicines 2019;7:E42. [PMID: 31212763 DOI: 10.3390/biomedicines7020042] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 12.3] [Reference Citation Analysis]
30 Tenembaum S, Yeh EA; Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC). Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis. Front Pediatr 2020;8:339. [PMID: 32671002 DOI: 10.3389/fped.2020.00339] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
31 Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 2021;20:60-7. [PMID: 33186537 DOI: 10.1016/S1474-4422(20)30392-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]